Bivalirudin Trifluoroacetate is primarily used as an anticoagulant in medical settings. It is commonly administered during percutaneous coronary interventions (PCI) such as angioplasty to prevent blood clotting. The compound is particularly beneficial for patients with heparin-induced thrombocytopenia (HIT), as it provides an alternative to heparin. It works by directly inhibiting thrombin, a key enzyme in the blood coagulation process, thereby reducing the risk of clot formation. Additionally, it is used in acute coronary syndromes to manage and prevent thrombotic complications. Its rapid onset and short half-life make it a preferred choice in scenarios where precise control over anticoagulation is required.